Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 1
1970 2
1973 2
1975 1
1977 1
1980 2
1981 1
1982 2
1984 3
1985 1
1986 1
1987 4
1988 4
1989 4
1990 6
1991 6
1992 7
1993 12
1994 7
1995 4
1996 7
1997 3
1998 10
1999 10
2000 11
2001 12
2002 5
2003 11
2004 4
2005 10
2006 7
2007 13
2008 7
2009 11
2010 11
2011 13
2012 9
2013 4
2014 11
2015 18
2016 11
2017 10
2018 3
2019 8
2020 11
2021 23
2022 6
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

322 results

Results by year

Filters applied: . Clear all
Page 1
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ. Mirza MR, et al. Among authors: rose pg. Cancer. 2023 Jun 15;129(12):1846-1855. doi: 10.1002/cncr.34706. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060236 Clinical Trial.
Endometrial carcinoma.
Rose PG. Rose PG. N Engl J Med. 1996 Aug 29;335(9):640-9. doi: 10.1056/NEJM199608293350907. N Engl J Med. 1996. PMID: 8692240 Review. No abstract available.
Management Strategies for Recurrent Endometrial Cancer.
Connor EV, Rose PG. Connor EV, et al. Among authors: rose pg. Expert Rev Anticancer Ther. 2018 Sep;18(9):873-885. doi: 10.1080/14737140.2018.1491311. Epub 2018 Jul 4. Expert Rev Anticancer Ther. 2018. PMID: 29972650 Review.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Among authors: rose pg. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Clinical Trial.
The flower looks as good as its bud.
Rose PG. Rose PG. Am J Obstet Gynecol. 2007 Nov;197(5):443-4. doi: 10.1016/j.ajog.2007.08.004. Am J Obstet Gynecol. 2007. PMID: 17980175 No abstract available.
322 results